Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2025
Biotech
ASH 2025 marked by ‘enduring activism’ and ‘cautious optimism’
While references to the Trump administration's attacks on science were prominent, an optimistic ASH was all about the data—and puppies.
Darren Incorvaia
Dec 9, 2025 3:15pm
Exicure scores in phase 2 multiple myeloma program
Dec 9, 2025 10:15am
ASH: Novartis details ianalumab's phase 3 rare blood disease win
Dec 9, 2025 7:30am
Fierce Pharma
ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma
Dec 9, 2025 7:30am
Lilly looks to become innovation ‘backbone,’ exec says
Dec 8, 2025 12:05pm
Amphista's targeted glue sticks the landing in early AML test
Dec 8, 2025 7:40am
